Nature Communication:靶向转录因子JunB抑制致病性TH17细胞导致的自免疫疾病

2017-06-01 MedSci MedSci原创

这一研究证明了JunB是依赖IL-23所分化的致病性TH17细胞的重要决定因素,有潜力成为治疗因致病性TH17细胞失衡产生的自身免疫性疾病的治疗靶点。

在各种CD4+的T辅助(T helper)细胞中,能够分泌细胞激素IL17的细胞被称为TH17细胞。早期研究对于其在机体和疾病模型中的表现,意见不一。一方面认为其为促进炎症导致疾病的细胞,另一方面认为其不具有明显的促炎功能。随着研究的进行,尽管TH17细胞共同的被RORγt转录因子控制调控其分化,但是根据其所分泌的细胞因子不同,TH17细胞被进一步归类为受TGFbeta和IL6所刺激分化的非致病性TH17(non-pathogenic T cell),和受IL6,IL1beta,IL23所刺激诱导分化的致病性TH17细胞。

通过移植这两种不同的TH17细胞到免疫缺陷的老鼠体内,致病性TH17细胞会引起强烈的免疫反应,包括肠炎和多发性硬化症,而非致病性TH17细胞则不会引起这类疾病。这两类细胞在各自的基因调控过程中,到底有什么不同并不是很清楚。

在最新的一期Nature Communication杂志中,Zafrul Hasan及其同事报道了他们的发现,属于AP-1转录因子的JunB蛋白在致病性TH17细胞中有更高的表达,并且对于其致病性至关重要。在致病性TH17细胞中,细胞因子IL-6会诱导JunB蛋白的表达,从而促进下游的转录因子BATF结合DNA,帮助对于致病性TH17细胞分化起到重要作用的RORγt和IL23受体的表达。但是,这一信号通路在受TGFβ1刺激所产生的非致病TH17细胞中则不存在。 

通过基因编辑,研究人员证明在缺乏Junb基因的T细胞中,不能被诱导成为致病性TH17细胞。而移植缺乏JunB基因的T细胞到实验小鼠中,则不能产生自身免疫性脑脊髓炎和结肠炎。然而,JunB缺乏症并不影响肠道非致病性TH17细胞的数量。 

这一研究证明了JunB是依赖IL-23所分化的致病性TH17细胞的重要决定因素,有潜力成为治疗因致病性TH17细胞失衡产生的自身免疫性疾病的治疗靶点。

原始出处:
Zafrul Hasan et al., JunB is essential for IL-23-dependent pathogenicity of Th17 cells. Nature Communications 8, Article number: 15628 (2017)doi:10.1038/ncomms15628

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747243, encodeId=0eed1e47243c1, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 07 00:54:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882125, encodeId=0b08188212573, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 26 07:54:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087049, encodeId=b8a3208e049ad, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 24 13:54:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718831, encodeId=c6b01e1883170, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Tue Apr 10 21:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413548, encodeId=57621413548ae, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511235, encodeId=c4ad151123545, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537467, encodeId=951b153e46793, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-12-07 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747243, encodeId=0eed1e47243c1, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 07 00:54:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882125, encodeId=0b08188212573, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 26 07:54:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087049, encodeId=b8a3208e049ad, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 24 13:54:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718831, encodeId=c6b01e1883170, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Tue Apr 10 21:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413548, encodeId=57621413548ae, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511235, encodeId=c4ad151123545, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537467, encodeId=951b153e46793, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2018-02-26 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747243, encodeId=0eed1e47243c1, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 07 00:54:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882125, encodeId=0b08188212573, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 26 07:54:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087049, encodeId=b8a3208e049ad, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 24 13:54:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718831, encodeId=c6b01e1883170, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Tue Apr 10 21:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413548, encodeId=57621413548ae, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511235, encodeId=c4ad151123545, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537467, encodeId=951b153e46793, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-07-24 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747243, encodeId=0eed1e47243c1, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 07 00:54:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882125, encodeId=0b08188212573, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 26 07:54:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087049, encodeId=b8a3208e049ad, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 24 13:54:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718831, encodeId=c6b01e1883170, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Tue Apr 10 21:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413548, encodeId=57621413548ae, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511235, encodeId=c4ad151123545, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537467, encodeId=951b153e46793, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2018-04-10 cnxcy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747243, encodeId=0eed1e47243c1, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 07 00:54:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882125, encodeId=0b08188212573, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 26 07:54:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087049, encodeId=b8a3208e049ad, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 24 13:54:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718831, encodeId=c6b01e1883170, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Tue Apr 10 21:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413548, encodeId=57621413548ae, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511235, encodeId=c4ad151123545, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537467, encodeId=951b153e46793, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-02 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747243, encodeId=0eed1e47243c1, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 07 00:54:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882125, encodeId=0b08188212573, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 26 07:54:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087049, encodeId=b8a3208e049ad, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 24 13:54:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718831, encodeId=c6b01e1883170, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Tue Apr 10 21:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413548, encodeId=57621413548ae, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511235, encodeId=c4ad151123545, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537467, encodeId=951b153e46793, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1747243, encodeId=0eed1e47243c1, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 07 00:54:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882125, encodeId=0b08188212573, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 26 07:54:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087049, encodeId=b8a3208e049ad, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 24 13:54:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718831, encodeId=c6b01e1883170, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Tue Apr 10 21:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413548, encodeId=57621413548ae, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511235, encodeId=c4ad151123545, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537467, encodeId=951b153e46793, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 02 23:54:00 CST 2017, time=2017-06-02, status=1, ipAttribution=)]